Apatinib Combined With Docetaxel in the Treatment of Advanced Esophageal Squamous Cell Carcinoma

NCT03193424 | Unknown Phase 2

• 1 other identifier: AHEAD-HNP001
• Study Type: interventional
• Target: 120
• Locations: 1 country
• Sites: 1

Brief Summary

Esophageal cancer is a common malignant tumor in china, occupies the second place of malignant tumor morbidity and mortality, the overall 5-year survival rate less than 20%.

Conditions

Advanced Esophageal Squamous Carcinoma

Outcome Measures

Primary Outcomes (1)

• Progression-free survival (PFS)

  The first day of treatment to the date that disease progression is reported.

  6 months

Secondary Outcomes (1)

• Total Survival (OS)

  up to 24 months

Study Arms (2)

Apatinib

EXPERIMENTAL

Drug: Apatinib

docetaxel

ACTIVE COMPARATOR

Drug: Apatinib

Interventions

Apatinib DRUG

Subjects were randomly divided into two groups,A group:apatinib 500mg/d,po,qd, Docetaxel 75 mg / m2 was administered on day 1 repeated every 21 days until progressive Disease(PD) . B group:Docetaxel 75 mg / m2 was administered on day 1 repeated every 21 days until progressive Disease(PD) .

Also known as: Docetaxel

Apatinib; docetaxel

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age: 18 years old to 75 years old, male and female is ok.
• Esophageal squamous cell carcinoma diagnosed by histopathology and immunohistochemistry. At least one treated measurable lesion (spiral CT scan length ≥10mm, in line with RESCIST version 1.1 standard requirements);
• Patients with advanced esophageal cancer treated by radiotherapy and treatment;
• ECOG PS Rating: 0-1 points;
• Expected survival ≥12 weeks;
• Without molecular targeted drug therapy.
• The main organ function is normal, that is to meet the following criteria:
• Blood test:a.HB≥90 g/L；b.ANC≥1.5×109/L；c.PLT ≥80×109/L； Biochemical tests:a.ALB≥30g / L；b. ALT和AST\<2ULN；ALT and AST \<2ULN;c.TBIL≤1.5ULN；Plasma Cr ≤ 1.5ULN;
• Subjects volunteered to join the study, signed informed consent, compliance, with follow-up.
• Researchers believe that patients can benefit.

You may not qualify if:

• Patients who have been confirmed to be allergic to apatinib and / or its excipients;
• Patients with uncontrollable hypertension (systolic blood pressure\> 140 mmHg, diastolic blood pressure\> 90 mmHg, despite optimal drug therapy), with grade Ⅱ myocardial ischemia or myocardial infarction, poor control of arrhythmias (including QTc interval male ≥ 450 ms, female ≥470 ms).According to NYHA standard, grade Ⅲ \~ Ⅳ heart failure, or cardiac color Doppler ultrasound examination showed left ventricular ejection fraction (LVEF) \<50%.
• Patients with a clear tendency to gastrointestinal bleeding, including the following: localized ulcer lesions, and fecal occult blood (++) can not be grouped; 2 months with black, hematemesis history;
• Coagulation dysfunction (INR\> 1.5, APTT\> 1.5 ULN), with bleeding tendency;
• (Eg, no swallowing, nausea, vomiting, chronic diarrhea and intestinal obstruction, etc.) that affect the absorption of oral medications;
• The patients with active brain metastases(without medical control) , cancer meningitis, spinal cord compression, or screening of imaging CT or MRI examination found that the brain or pia mater disease (21 days before the completion of treatment and symptoms of stable brain Metastasis patients can be grouped, but the need for transcranial MRI, CT or intravenous angiography, confirmed as no cerebral hemorrhage symptoms)
• Pregnant or lactating women
• Subject with other malignancies within 5 years(except the skin basal cell carcinoma and cervical in situ cancer that have already cured )
• Subject with a history of psychiatric abuse and who can not be abused or have mental disorders;
• Subject who participated in other drug clinical trials within 4 weeks.
• Subject who have received VEGFR inhibitors such as sorafenib, sunitinib;
• According to the investigator's judgment, there are serious illnesses that compromise the patient's safety or affect the patient's completion of the study;

Sponsors & Collaborators

• The First Affiliated Hospital of Zhengzhou University: lead

Study Sites (1)

FirstAHZhengzhouU

Zhengzhou, Henan, 450000, China

RECRUITING

MeSH Terms

Interventions

apatinib; Docetaxel

Intervention Hierarchy (Ancestors)

Taxoids; Cyclodecanes; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals; Diterpenes; Terpenes

Central Study Contacts

Qingxia Fan

CONTACT

13939039058; fqx2243@126.com

Lijie Song

CONTACT

13939020459; lijiesongcn@hotmail.com

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Director

Model Details: Double Group Assignment,apatinib plus docetaxel comparison to docetaxel.

Study Record Dates

• First Submitted: June 17, 2017
• First Posted: June 20, 2017
• Study Start: October 1, 2016
• Primary Completion: December 30, 2018
• Study Completion: December 30, 2019
• Last Updated: June 20, 2017

Record last verified: 2017-06

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)